CompletedPhase 4

Intranasal Steroids and Oxymetazoline in Allergic Rhinitis

United States64 participantsStarted 2007-06

Plain-language summary

We hypothesize that once daily use of oxymetazoline will not cause significant rhinitis medicamentosa and that the combination of fluticasone furoate plus oxymetazoline leads to faster relief of nasal congestion secondary to perennial allergic rhinitis than the use of fluticasone furoate alone.

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Males and females between 18 and 55 years of age.
✓. History of perennial allergic rhinitis.
✓. Positive skin test to dust mite, dog, cat or indoor mold antigen.
✓. And a combined nasal morning and evening score of ≥4 for nasal congestion in the day preceding entry

Exclusion criteria

✕. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
✕. Pregnant or lactating women.
✕. Subjects treated with systemic steroids during the previous 30 days.
✕. Subjects treated with topical (inhaled, intranasal or intraocular) steroids, Nasalcrom or Opticrom during the previous 30 days.
✕. Subjects treated with oral antihistamine/decongestants during the previous seven days.
✕. Subjects treated with topical (intranasal or intraocular) antihistamine/decongestants during the previous 3 days.
✕. Subjects treated with immunotherapy and are escalating their dose.
✕. Subjects on chronic anti-asthma medications.

What they're measuring

Total Nasal Congestion Symptom Score

Timeframe: 28 days of treatment

Trial details

NCT IDNCT00584987

SponsorUniversity of Chicago

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-07

Results submitted2013-07-08

View on ClinicalTrials.gov More Allergic Rhinitis trials